阿奇霉素联合头孢曲松钠治疗儿童难治性肺炎支原体肺炎的临床应用价值

目的 探讨阿奇霉素联合头孢曲松钠治疗儿童难治性肺炎支原体肺炎的临床应用价值.方法 将2011年12月至2012年12月期间本院收诊的73例难治性肺炎支原体肺炎患儿随机分成两组,对照组35例,观察组38例；对照组采用阿奇霉素治疗,观察组则采用阿奇霉素联合头孢曲松钠治疗.比较两组间的疗效、症状改善时间差异及住院时间,随访6个月统计病情反复例数.结果 治疗1个疗程后,观察组总有效率为94.74％,显著高于对照组的71.43％,P＜0.05.观察组患儿咳嗽消失时间、退热时间、肺部啰音消失时间、住院时间等显著短于对照组（P ＜0.05）；随访6个月,观察组病情反复率为18.42％,显著低于对照组的40.00％,P＜0.05.结论 阿奇霉素联合头孢曲松钠治疗儿童难治性肺炎支原体肺炎疗效好,能有效缩短症状改善时间和住院时间并降低病情反复率,具有较高的临床应用价值.

Clinical Value of Azithromycin Combined with Ceftriaxone in the Treatment of Children with Refractory Mycoplasma Pneumonia

Objective To investigate the clinical value of azithromycin combined with ceftriaxone in the treatment of children with refractory mycoplasma pneumonia, Methods Seventy-three patients with refractory mycoplasma pneumonia from December 2011 to December 2012 were randomly divided into two groups. 35 cases of the control group were treated with azithromycin, while 38 cases of the observation group were treated with azitbxomycin combined with ceftria~one. The difference in efficacy, the symptoms improved time and hospitalization time of the two groups were compared. At 6 months of follow-up, the number of repeated illness was taken for statistics. Results After a course of treatment, the total effective rate in the observation group was 94.74%, significantly higher than 71.43% in the control group, P 〈0.05. The cough disappeared time, cooling time, pulmonary rales disappeared time and hospitalization time in the observation group was significantly shorter than those in the control group. Following up for 6 months, the recurrent disease rate in the observation group was 18.42%, significantly lower than 40.00% n the control group, P 〈0.05. Conclusions Azithromyein combined with ceftriaxone in the treatment of children with refractory mycoplasma pneumonia has better clinical efficacy, which can effectively reduce the symptoms improved time and hospitalization time and lower the recurrent disease rate with a high clinical value.